Park, Bo Ryoung
Bommireddy, Ramireddy
Chung, David Hyunjung
Kim, Ki-Hye
Subbiah, Jeeva
Jung, Yu-Jin
Bhatnagar, Noopur
Pack, Christopher D.
Ramachandiran, Sampath
Reddy, Shaker J.C.
Selvaraj, Periasamy
Kang, Sang-Moo
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (75N93019C00017, 75N93019C00017, 75N93019C00017, 75N93019C00017, 75N93019C00017)
Article History
Received: 24 December 2022
Accepted: 24 April 2023
First Online: 11 May 2023
Declarations
:
: Not applicable.
: Not applicable.
: PS and SJCR are the co-founders of the Metaclipse Therapeutics Corporation (MTC) and hold equity and stock options. Dr. Periasamy Selvaraj is a co-founder & equity holder of Metaclipse Therapeutics Corporation- a company formed to develop cancer vaccines and viral vaccines using the protein transfer technology and membrane anchored cytokines as novel vaccine adjuvants for humans as described here for which he is a co-inventor.CP and SR declare competing financial interests in the form of stock ownership and paid employment by Metaclipse Therapeutics Corporation. One or more embodiments of one or more patents and patent applications filed by Metaclipse, and Emory University may encompass the methods, reagents, and data disclosed in this manuscript.All other authors have no competing interests to declare.